Kairos Pharma reports zero Grade 3+ toxicities from ENV-105 in Phase 1 NSCLC trial

Kairos Pharma, LTD.

Zero Grade 3+ toxicities from ENV-105 in 13 patients with advanced EGFR-mutated NSCLC.
ENV-105 (carotuximab) combined with osimertinib (Tagrisso) shows clean safety profile.
Targets $10B drug resistance market; no FDA-approved agent to reverse osimertinib resistance.
Phase 1 trial ongoing; safety data supports continued development toward efficacy readout.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.